Starkman et al reported a prognostic score for a patient with the myelodysplastic syndrome (MDS). The authors are from multiple institutions in Canada.
Patient selection: myelodysplasia
Parameters:
(1) age of the patient in years
(2) MDS frailty index of Starkman et al, from 0 to 1
(3) International Prognostic Scoring System (IPSS) for Myelodysplasia
(4) transfusion dependency status
Parameter |
Finding |
Points |
age |
< 70 years |
0 |
|
>= 70 years |
0.5 |
frailty index |
<= 0.2 |
0 |
|
0.21 to 0.3 |
0.5 |
|
> 0.3 |
1 |
IPSS |
low |
0 |
|
intermediate-1 |
0.5 |
|
intermediate-2 |
1 |
|
high |
2 |
transfusion |
independent |
0 |
|
dependent |
0.5 |
total score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 4
• The higher the score the worse the overall survival.
• A patient with a score >= 3 has a 4-year overall survival rate that is very low.
Score |
Prognostic Group |
24-Month Overall Survival |
0 |
1 (very good) |
94% |
0.5 |
2 (fair) |
74% |
1 |
3 |
66% |
1.5 to 2.5 |
4 |
34% |
3 to 4 |
5 (poor) |
13% |
Specialty: Hematology Oncology